CD33 and acute myeloid leukemia: Given the rapid re-expression on the CD33 antigen after GO exposure [14,17], a phase II trial addressed the efficacy of fractionated GO (3 mg/m2 on days 1, 4 and 7) in adults with relapsed AML [26].